Get the Stockscreener App
0.75
3.77%
-0.0294
Pre-market:
.77
0.02
+2.67%
Adicet Bio Inc stock is traded at $0.75, with a volume of 2.82M.
It is down -3.77% in the last 24 hours and down -7.43% over the past month.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
See More
Previous Close:
$0.7794
Open:
$0.783
24h Volume:
2.82M
Relative Volume:
2.00
Market Cap:
$62.44M
Revenue:
$24.99M
Net Income/Loss:
$-118.64M
P/E Ratio:
-0.5725
EPS:
-1.31
Net Cash Flow:
$-100.25M
1W Performance:
-15.73%
1M Performance:
-7.43%
6M Performance:
+13.28%
1Y Performance:
-41.41%
1-Day Range:
$0.7302
$0.809
1-Week Range:
$0.7302
$0.91
52-Week Range:
$0.4471
$1.40
Adicet Bio Inc Stock (ACET) Company Profile
Name
Adicet Bio Inc
Sector
Industry
Phone
617-482-2333
Address
131 DARTMOUTH STREET, BOSTON
Compare ACET with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACET
Adicet Bio Inc
|
0.75 | 119.45M | 24.99M | -118.64M | -100.25M | -1.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Adicet Bio Inc Stock (ACET) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-30-24 | Resumed | Guggenheim | Buy |
| Sep-11-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-27-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-27-23 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Mar-31-22 | Initiated | SMBC Nikko | Outperform |
| Mar-08-22 | Initiated | Truist | Buy |
| Mar-04-22 | Initiated | Jefferies | Buy |
| May-18-21 | Initiated | BTIG Research | Buy |
| Apr-23-21 | Initiated | H.C. Wainwright | Buy |
| Apr-14-21 | Initiated | Canaccord Genuity | Buy |
| Apr-08-21 | Initiated | Guggenheim | Buy |
| Nov-04-20 | Initiated | B. Riley Securities | Buy |
| Oct-27-20 | Initiated | JMP Securities | Mkt Outperform |
| Oct-16-20 | Initiated | Wedbush | Outperform |
View All
Adicet Bio Inc Stock (ACET) Latest News
Can Adicet Bio Inc. stock maintain growth trajectoryJuly 2025 Spike Watch & Community Consensus Trade Signals - newser.com
Will breakout in Adicet Bio Inc. lead to full recoveryTrade Ideas & Fast Moving Trade Plans - newser.com
Can trapped investors hope for a rebound in Adicet Bio Inc.July 2025 News Drivers & Smart Money Movement Alerts - newser.com
Price momentum metrics for Adicet Bio Inc. explainedJuly 2025 Fed Impact & Consistent Profit Alerts - newser.com
Risk adjusted return profile for Adicet Bio Inc. analyzedWeekly Trend Recap & Daily Oversold Bounce Ideas - newser.com
Historical volatility pattern of Adicet Bio Inc. visualizedQuarterly Market Summary & Stepwise Entry and Exit Trade Signals - newser.com
Can Adicet Bio Inc. (1IJA) stock double in coming yearsJuly 2025 Retail & Weekly High Return Stock Opportunities - newser.com
How Adicet Bio Inc. (1IJA) stock valuation compares with sector2025 Fundamental Recap & Reliable Intraday Trade Alerts - newser.com
How analysts revise price targets for Adicet Bio Inc. (1IJA) stock2025 Investor Takeaways & Consistent Growth Stock Picks - newser.com
Will Adicet Bio Inc. stock benefit from green energy trends2025 Geopolitical Influence & Consistent Growth Equity Picks - newser.com
Adicet Bio (NASDAQ:ACET) Shares Cross Above Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Adicet Bio Inc 1IJA Stock Analysis and ForecastTechnical Analysis Insights & Free Real-Time Trading Signals - earlytimes.in
How supply chain issues affect Adicet Bio Inc. stockDay Trade & AI Enhanced Trading Signals - newser.com
Adicet Bio, Inc. (NASDAQ:ACET) Short Interest Update - MarketBeat
Can Adicet Bio Inc. stock outperform in 2025 bull marketOil Prices & Detailed Earnings Play Strategies - newser.com
How Adicet Bio Inc. stock valuations compare to rivalsJuly 2025 Spike Watch & Weekly Chart Analysis and Trade Guides - newser.com
Will Adicet Bio Inc. stock return to pre crisis levelsTrade Entry Report & High Accuracy Trade Alerts - newser.com
How strong is Adicet Bio Inc. stock revenue growth2025 Fundamental Recap & AI Driven Stock Reports - newser.com
Why Adicet Bio Inc. (1IJA) stock could rally stronglyMarket Activity Recap & Stepwise Entry and Exit Trade Signals - newser.com
Adicet Bio reports inducement grants under Nasdaq listing rule 5635(c)(4) - MarketScreener
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Globe and Mail
Adicet Bio (Nasdaq: ACET) grants options for 97,200 shares and four-year vesting - Stock Titan
Adicet Bio (NASDAQ:ACET) Given Sell (D-) Rating at Weiss Ratings - MarketBeat
Why Adicet Bio Inc. (1IJA) stock remains top ratedJuly 2025 Rallies & Real-Time Volume Spike Alerts - newser.com
Can Adicet Bio Inc. stock beat market expectations this quarterTrade Entry Summary & Reliable Volume Spike Trade Alerts - newser.com
Adicet Bio (ACET) Expected to Announce Earnings on Wednesday - MarketBeat
How Adicet Bio Inc. stock reacts to oil pricesWeekly Volume Report & Weekly High Conviction Ideas - newser.com
Adicet Bio Inc Stock (ACET) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):